Aussi at Harvard. Moir., page-3

First 3 Last

Share
Profile

Follow
skint

3,630 Posts.

116

14/11/18

11:34

Post #: 36498439
Share

Originally posted by skint: ↑

“It used to be thought that stopping the plaques early was ‘primary prevention,’” Tanzi said. “I think primary prevention is stopping the microbes.” Treatment would mean leaving amyloid mostly alone (since it protects the brain from herpes and other viruses) but targeting inflammation, a biological fire that “kills 10 neurons for every one killed by amyloid and tau directly,” he said. “Neuroinflammation is where we’re going to find [Alzheimer’s] drugs. PolicyTanzi chairs the scientific advisory board of AZTherapies, a Boston-based biotech that is recruiting patients with early Alzheimer’s for a clinical trial testing whether inhaling a powdered form of the immune-targeting drug cromolyn reduces dementia. (The nose connects to the brain.)One reviewer of Moir’s latest NIH grant proposal called it “fascinating and innovative,” with “the potential for answering the vital question” of what causes late-onset Alzheimer’s. (The early-onset form is genetic.) Moir, the reviewer said, “has consistently produced creative, thought-provoking work.”Another, however, slammed the proposed research, questioning whether it “will be relevant to understand AD pathogenesis” since, in his view, amyloid formation might not matter in Alzheimer’s. (It’s the disease’s defining trait.)The proposal was turned down in June. “One bad review can sink a new and innovative idea just because it’s new and innovative,” Moir said matter-of-factly. He can’t work up much animosity anymore.
This month, however, he got an unheard-of email from NIH: The agency had found some extra money lying around in its budget. Would he please respond to the reviewers and resubmit his proposal? An over-the-moon Moir did. He expects to hear back in a few weeks.

Expand

Prana's PBT2 does not attack the amyloid, but competed with amyloid for transition metals which it could chaperone back to where they are needed. Over 10 years ago Tanzi seemed to be aware that MABs designed to directly attack AB were the wrong way to go. He(and Prana) were so far ahead of the field back then, but that was in the GFC of 2008 and the money had dried up.

PBT Price at posting: 4.2¢ Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

DUI

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

HotCopper Highlights: Your most watched stocks for Week 47, 2024

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

PYC

Scientific conference spotlights PYC's work on blindness disease treatment

There are more pages in this discussion • 6 more messages in this thread...

First 3 Last

Add PBT (ASX) to my watchlist

Aussi at Harvard. Moir., page-3

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

HotCopper Highlights: Your most watched stocks for Week 47, 2024

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Sales growth pushes Lovisa's fortunes (and shares) upwards

Scientific conference spotlights PYC's work on blindness disease treatment

Featured News